Update shared on08 Aug 2025
Fair value Increased 14%Upward revisions to Compugen's revenue growth and net profit margin forecasts have driven a notable increase in its consensus analyst price target, which has risen from $5.50 to $6.25.
What's in the News
- Compugen dosed the first patient in a global randomized sub-trial (MAIA-ovarian), evaluating its potential first-in-class anti-PVRIG antibody COM701 as maintenance therapy for relapsed platinum sensitive ovarian cancer.
- The MAIA-ovarian adaptive platform trial assesses safety and efficacy of COM701 as monotherapy or in combination, with sub-trial 1 enrolling 60 patients and enabling future sub-trials.
- Key leadership transitions announced: Anat Cohen-Dayag will become Executive Chair (pending approval), and Eran Ophir, currently Chief Scientific Officer, will assume the role of CEO.
- Cohen-Dayag will focus on corporate strategy, strategic collaborations, and investor relations; Ophir has been central to Compugen’s research and development efforts and immuno-oncology pipeline.
Valuation Changes
Summary of Valuation Changes for Compugen
- The Consensus Analyst Price Target has significantly risen from $5.50 to $6.25.
- The Consensus Revenue Growth forecasts for Compugen has significantly risen from 10.2% per annum to 18.8% per annum.
- The Net Profit Margin for Compugen has significantly risen from 12.02% to 13.95%.
Disclaimer
AnalystConsensusTarget is a tool utilizing a Large Language Model (LLM) that ingests data on consensus price targets, forecasted revenue and earnings figures, as well as the transcripts of earnings calls to produce qualitative analysis. The narratives produced by AnalystConsensusTarget are general in nature and are based solely on analyst data and publicly-available material published by the respective companies. These scenarios are not indicative of the company's future performance and are exploratory in nature. Simply Wall St has no position in the company(s) mentioned. Simply Wall St may provide the securities issuer or related entities with website advertising services for a fee, on an arm's length basis. These relationships have no impact on the way we conduct our business, the content we host, or how our content is served to users. The price targets and estimates used are consensus data, and do not constitute a recommendation to buy or sell any stock, and they do not take account of your objectives, or your financial situation. Note that AnalystConsensusTarget's analysis may not factor in the latest price-sensitive company announcements or qualitative material.